HK1199821A1 - Oral pharmaceutical composition - Google Patents

Oral pharmaceutical composition

Info

Publication number
HK1199821A1
HK1199821A1 HK15100293.7A HK15100293A HK1199821A1 HK 1199821 A1 HK1199821 A1 HK 1199821A1 HK 15100293 A HK15100293 A HK 15100293A HK 1199821 A1 HK1199821 A1 HK 1199821A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical composition
oral pharmaceutical
oral
composition
pharmaceutical
Prior art date
Application number
HK15100293.7A
Other languages
English (en)
Chinese (zh)
Inventor
大西敬人
尾形哲夫
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48984244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1199821(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of HK1199821A1 publication Critical patent/HK1199821A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK15100293.7A 2012-02-15 2015-01-12 Oral pharmaceutical composition HK1199821A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012031144 2012-02-15
PCT/JP2013/053514 WO2013122135A1 (ja) 2012-02-15 2013-02-14 経口用医薬組成物

Publications (1)

Publication Number Publication Date
HK1199821A1 true HK1199821A1 (en) 2015-07-24

Family

ID=48984244

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15100293.7A HK1199821A1 (en) 2012-02-15 2015-01-12 Oral pharmaceutical composition

Country Status (24)

Country Link
US (3) US20140363512A1 (hr)
EP (1) EP2815752B1 (hr)
JP (1) JP5798642B2 (hr)
KR (1) KR101740105B1 (hr)
CN (1) CN104105490A (hr)
AU (1) AU2013219296B2 (hr)
CA (1) CA2863018C (hr)
CY (1) CY1123372T1 (hr)
DK (1) DK2815752T3 (hr)
ES (1) ES2804674T3 (hr)
HK (1) HK1199821A1 (hr)
HR (1) HRP20201140T1 (hr)
HU (1) HUE050840T2 (hr)
LT (1) LT2815752T (hr)
MX (1) MX365313B (hr)
MY (1) MY155938A (hr)
PL (1) PL2815752T3 (hr)
PT (1) PT2815752T (hr)
RS (1) RS60552B1 (hr)
RU (1) RU2639473C2 (hr)
SG (1) SG11201403875VA (hr)
SI (1) SI2815752T1 (hr)
TW (1) TWI526210B (hr)
WO (1) WO2013122135A1 (hr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI526210B (zh) 2012-02-15 2016-03-21 Taiho Pharmaceutical Co Ltd Oral pharmaceutical composition
CN106551946B (zh) * 2015-09-24 2020-02-14 江苏奥赛康药业有限公司 一种含三氟胸苷和盐酸替比嘧啶的药物组合物及制备方法
CN106913580A (zh) * 2015-12-27 2017-07-04 南京圣和药业股份有限公司 一种含曲氟尿苷盐酸替哌拉索的药物组合物及其应用
CN106018573B (zh) * 2016-03-16 2018-09-18 江苏悦兴药业有限公司 一种tas-102中盐酸替比拉西的纯度检测方法
CN105963271A (zh) * 2016-06-01 2016-09-28 国药心制药有限公司 一种药用辅料组合物及一种曲氟尿苷、盐酸替匹嘧啶薄膜衣片
US10866219B2 (en) 2017-12-22 2020-12-15 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine- and/or tipiracil-related substance
WO2019124544A1 (ja) 2017-12-22 2019-06-27 大鵬薬品工業株式会社 トリフルリジン及び／又はチピラシル由来の類縁物質の検出方法
WO2019135405A1 (ja) 2018-01-05 2019-07-11 大鵬薬品工業株式会社 トリフルリジン由来の類縁物質の検出方法
US10816517B2 (en) 2018-01-05 2020-10-27 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine-related substance by high-performance liquid chromatography
US11730753B2 (en) * 2018-03-03 2023-08-22 Natco Pharma Limited Stable pharmaceutical compositions comprising trifluridine and tipiracil hydrochloride
CN114917201B (zh) * 2022-06-14 2024-05-31 国药一心制药有限公司 一种曲氟尿苷替匹嘧啶片剂及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
JP3088757B2 (ja) * 1995-03-29 2000-09-18 大鵬薬品工業株式会社 ウラシル誘導体並びにそれを含有する抗腫瘍効果増強剤及び抗腫瘍剤
JPH11322604A (ja) * 1998-05-06 1999-11-24 Pola Chem Ind Inc ジフェニルピペラジン化合物を含有する製剤
JP4110347B2 (ja) 1999-11-05 2008-07-02 大鵬薬品工業株式会社 抗ｈｉｖ剤
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
JP4601934B2 (ja) * 2003-10-06 2010-12-22 ナガセ医薬品株式会社 ユビデカレノン錠
JP2005314413A (ja) * 2004-04-02 2005-11-10 Ono Pharmaceut Co Ltd 経口投与用医薬組成物
AU2006209547C1 (en) * 2005-01-26 2022-04-07 Taiho Pharmaceutical Co., Ltd. Anticancer drug containing alpha,alpha,alpha-trifluorothymidine and thymidine phosphorylase inhibitor
US7799783B2 (en) * 2005-01-26 2010-09-21 Taiho Pharmaceutical Co., Ltd. Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
JP2007284390A (ja) * 2006-04-18 2007-11-01 Ohara Yakuhin Kogyo Kk 塩酸イミダプリル含有錠剤
RU2435587C2 (ru) * 2006-06-30 2011-12-10 Тайхо Фармасьютикал Ко., Лтд. Средство, потенцирующее радиационную терапию
RU2346684C2 (ru) * 2007-04-04 2009-02-20 Закрытое акционерное общество "Биологические исследования и системы" Фармацевтическая композиция на основе сигетина
TWI526210B (zh) 2012-02-15 2016-03-21 Taiho Pharmaceutical Co Ltd Oral pharmaceutical composition

Also Published As

Publication number Publication date
RU2639473C2 (ru) 2017-12-21
MX365313B (es) 2019-05-29
HUE050840T2 (hu) 2021-01-28
EP2815752A1 (en) 2014-12-24
TW201336499A (zh) 2013-09-16
BR112014017633A8 (pt) 2021-02-23
EP2815752A4 (en) 2015-07-29
US20200289411A1 (en) 2020-09-17
MX2014009834A (es) 2014-09-11
AU2013219296B2 (en) 2016-05-26
TWI526210B (zh) 2016-03-21
PT2815752T (pt) 2020-07-15
EP2815752B1 (en) 2020-05-20
US20140363512A1 (en) 2014-12-11
KR101740105B1 (ko) 2017-05-25
SG11201403875VA (en) 2014-10-30
CY1123372T1 (el) 2021-12-31
JP5798642B2 (ja) 2015-10-21
RU2014137158A (ru) 2016-04-10
ES2804674T3 (es) 2021-02-09
MY155938A (en) 2015-12-17
PL2815752T3 (pl) 2020-11-16
JPWO2013122135A1 (ja) 2015-05-18
SI2815752T1 (sl) 2020-08-31
CA2863018A1 (en) 2013-08-22
US20220218602A1 (en) 2022-07-14
LT2815752T (lt) 2020-08-10
CN104105490A (zh) 2014-10-15
KR20150001718A (ko) 2015-01-06
DK2815752T3 (da) 2020-07-20
RS60552B1 (sr) 2020-08-31
HRP20201140T1 (hr) 2020-10-30
WO2013122135A1 (ja) 2013-08-22
CA2863018C (en) 2020-01-07
AU2013219296A1 (en) 2014-07-24

Similar Documents

Publication Publication Date Title
HK1209638A1 (en) Pharmaceutical compositions
HK1207819A1 (en) Oral composition
ZA201501930B (en) Pharmaceutical composition
HK1199821A1 (en) Oral pharmaceutical composition
HRP20181193T1 (hr) Farmaceutska kompozicija koja se može oralno administrirati
EP2832730A4 (en) MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
IL266415A (en) Innovative pharmaceutical composition
ZA201502987B (en) Pharmaceutical composition
EP2897590A4 (en) PHARMACEUTICAL COMPOSITION
EP2859881A4 (en) ORAL COMPOSITION
GB201211153D0 (en) Pharmaceutical compositions
EP2851078A4 (en) PHARMACEUTICAL COMPOSITION
IL238075A0 (en) pharmaceutical preparations
ZA201400751B (en) Pharmaceutical composition
GB201221130D0 (en) New pharmaceutical composition
GB201207701D0 (en) New pharmaceutical composition
GB201207628D0 (en) New pharmaceutical composition
GB201219234D0 (en) Pharmaceutical compositions
GB201213303D0 (en) Pharmaceutical compositions
GB201204810D0 (en) Pharmaceutical compositions